- $5.10m
- -$4.98m
- $1.20m
Longeveron rises as Alzheimer's therapy succeeds in mid-stage study
Brief: Longeveron Announces Positive Top-Line Results For Lomecel-B™ In Its Phase 2A Clinical Trial for Mild Alzheimer’S Treatment
Brief: Longeveron- Long-Term Survival Data From Elpis 1 Trial Accepted For Presentation At 2023 Scientific Sessions Of American Heart Association
Brief: Longeveron Announces Pricing For Rights Offering And Expected Calendar
Brief: Longeveron Appoints Lisa Locklear As Chief Financial Officer
Factbox: Companies in Alzheimer's race after US nod for Eisai/Biogen drug
Brief: Longeveron Inc Says Registration Statement On Form S-1 Covers A Rights Offering For Up To $30 Million Of Shares Of Common Stock
Brief: Longeveron Says James Clavijo To Continue As Interim CFO Beyond June 9
U.S. STOCKS ON THE MOVE-DXP Enterprises, Holley, Augmedix
U.S. STOCKS ON THE MOVE-Arlo Technologies, Old Republic, Clearmind Medicine
Longeveron falls on wider Q1 loss
Brief: Longeveron Inc Reports First Quarter 2023 Financial Results
Brief: Longeveron Announces New Long-Term Survival Data From Elpis I Trial Of Lomecel-B For Hypoplastic Left Heart Syndrome
Brief: Longeveron Announces First Patient Dosed In Phase 2 Clinical Trial Of Lomecel-B™ For Aging-Related Frailty In Japan
Brief: Longeveron Inc Says On April 4, James Clavijo, CFO Of Co Provided Notice Of Intention To Resign, Effective June 9
Brief: Longeveron Appoints Wa’El Hashad As Chief Executive Officer
Brief: Longeveron Announces Publication Of Final Data From Elpis I Trial Of Lomecel-Btm For Hypoplastic Left Heart Syndrome In Peer-Reviewed Journal
Brief: Longeveron Inc. Provides Corporate Update And Reports Third Quarter 2022 Financial Results
Brief: Longeveron Announces Completion Of Enrollment In Phase 2A Trial Of Lomecel-B For Treatment Of Alzheimer's Disease